Payment overview · 2025
General Payments
$690.49
20 reported records · 6 companies
Healthcare provider profile · identity verified
Yoichi Christopher Soma, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HONOLULU, HI · NPI 1497809032
Verified facts
What the public records show
CMS Open Payments records show Yoichi Christopher Soma, M.D. received $690.49 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Paxlovid.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $285.55 | 41.4% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $223.77 | 32.4% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.85 | 17.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.43 | 3.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.01 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.88 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $690.49 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $223.77 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $174.84 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.71 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
25 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 479 | 168 |
| Losartan Potassium | Losartan Potassium | 318 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 106 |
| Prednisone | Prednisone | 164 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 159 | 49 |
| Alendronate Sodium | Alendronate Sodium | 136 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 43 |
| Omeprazole | Omeprazole | 111 | 47 |
| Metformin Hcl Er | Metformin Hcl | 108 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 93 | 31 |
| Jardiance | Empagliflozin | 88 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 27 |
| Azithromycin | Azithromycin | 72 | 69 |
| Lisinopril | Lisinopril | 67 | 19 |
| Metformin Hcl | Metformin Hcl | 65 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 29 |
| Azelastine Hcl | Azelastine Hcl | 57 | 25 |
| Alprazolam | Alprazolam | 56 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 17 |
| Glipizide Er | Glipizide | 52 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 18 |
| Famotidine | Famotidine | 45 | 12 |
| Lactulose | Lactulose | 42 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 27 |
| Meloxicam | Meloxicam | 38 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 29 |
| Gabapentin | Gabapentin | 35 | 17 |
| Diazepam | Diazepam | 34 | suppressed |
| Eliquis | Apixaban | 34 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | 13 |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | 12 |
| Donepezil Hcl | Donepezil Hcl | 30 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 11 |
| Furosemide | Furosemide | 29 | 16 |
| Meclizine Hcl | Meclizine Hcl | 28 | 18 |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Simvastatin | Simvastatin | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Prolia | Denosumab | 25 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 24 | 24 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Fluocinonide | Fluocinonide | 20 | 17 |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | 11 |
| Trulicity | Dulaglutide | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 13 | 12 |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 12 |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $690.49 · 20 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, EVENITY, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error